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We report the smallest infant (4.5 kg) to receive leukapheresis as an immediate treatment for Infantile Acute
Lymphocytic Leukemia. Leukodepletion helps prevent the risks of hyperviscosity and cerebrovascular and pulmo-
nary leukostasis. In addition, it is a desirable precursor to chemotherapy to potentially reduce metabolic and renal
complications associated with rapid cell lysis. Because of this infant’s small size, she presented us with multiple
concerns, including hypocalcemia from citrate anticoagulation, extracorporeal volume and fluid balance, inlet flow
rates. and establishment of adequate interface. Our positive experience in performing this procedure suggests that
cytapheresis is a feasible treatment even for very young infants. J. Clin. Apheresis. 16:31-32, 2001.
© 2001 Wiley-Liss, Inc.
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INTRODUCTION
Therapeutic leukapheresis decreases the numbers of
circulating white blood cells, which helps prevent leu-
kostasis and hyperviscosity. As an adjunct to chemo-
therapy, leukapheresis potentially reduces the metabolic
and renal complications associated with rapid cellular
lysis [1]. However, experience with leukodepletion in
infants, especially newborns, is limited. Thus, we detail
our successful experience with a 3-week-old diagnosed
with Infantile Acute Lymphocytic Leukemia, and how
team effort gave this child a chance to live.
CASE REPORT
During a routine check-up, this three-week-old, 4.5kg,
white female presented with a new erythematous rash on
her back. A CBC drawn in the physician’s office re-
vealed a white blood cell count of greater than 100,000.
The baby was sent to our emergency room and was ad-
mitted for work up of possible leukemia. Laboratory val-
ues included WBC, 567.9 K/mm3; hematocrit, 38%;
platelets, 70 K/mm3; calcium, 11.3 mg/dl; potassium, 3.8
meq/ml; and sodium, 142 meq/ml. Over the next 12
hours, the WBC stayed in the 550s and the differential
showed an absolute blast count of 562.2 or 99%. The
attending hematologists requested leukodepletion to re-
duce risks of leukostasis and prepare the child for che-
motherapy.
An immediate pre-apheresis blood count revealed
WBC, 551.1 K/mm3; hematocrit, 25%; platelets, 45
K/mm3; potassium, 2.6 meq/ml; sodium, 137 meq/ml;
and LDH, 2,020 IU/L.
One hour into leukodepletion, the patient’s WBC had
dropped to 251.3 K/mm3, hematocrit was 30%; and
platelet count was 22 K/mm3. Immediately after the
2-hour procedure, the CBC showed WBC, 116.4 K/mm3;
hct., 24%; platelet count, and 22 K/mm3. The ionized
calcium was 1.22; potassium, 2.5; and sodium, 139. Fluid
balance was maintained at plus 2 ml. Chemotherapy was
initiated. One week post leukapheresis, the infant was
doing well and has an excellent prognosis for recovery.
DISCUSSION
Having never performed apheresis on a baby younger
than 9 months, our staff had serious reservations about
potential risks of the procedure. Initially, it was felt that
exchange transfusion might be a safer and similarly ef-
fective treatment. When the physicians ruled out this op-
tion, the child was sent to the operating room for dialysis
catheter placement.
Obtaining adequate venous access became the first
obstacle. Attempts by the surgeons to place femoral lines
proved unsuccessful. With due consideration to the risks
and benefits, the neonatology staff decided to paralyze,
intubate, and anesthetize the baby to allow for placement
of a larger catheter.
Meanwhile, the apheresis staff brainstormed, discuss-
ing all potential problems and resolutions. This infant, at
4.5 kg and 53cm, had a total blood volume of approxi-
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mately 400 ml. The extracorporeal volume of our COBE
Spectra WBC kit is 284 ml not inclusive of the blood
warmer. We knew our standard RBC prime would es-
sentially add a 70% hematocrit product to this child’s
already viscous blood. Therefore, we opted for leuko-
cyte-reduced, irradiated whole blood, reconstituted from
RBCs and FFP, with a hematocrit of 40%.
Depleting the child’s platelets was a potential prob-
lem, not only due to the blood prime but also by virtue of
the procedure itself, which removes some platelets in the
buffy coat layer. We decided to run a CBCPD during the
procedure and have platelets ready for transfusion.
Citrate toxicity was a major risk since a fairly large
volume of ACD-A is infused in the course of a leukocyte
procedure. We have witnessed dramatic drops in ionized
calcium levels of even larger children during white cell
collections. As part of our SOP, we routinely measure
ionized calcium levels every 30–45 minutes throughout
pediatric apheresis and titrate a calcium gluconate drip to
maintain the ionized calcium at 1.0–1.3. However, be-
cause of the child’s very small blood volume, we asked
for assistance from the hemodialysis team to systemi-
cally heparinize the infant, thus, avoiding the use of ci-
trate and negating the potential for hypocalcemia.
We then began to address fluid replacement concerns.
During aggressive leukodepletion, we maintained iso-
volemia by replacing volume with 5% Albumin. The
COBE-BCT technical staff, with whom we had con-
sulted, suggested that we utilize the anticoagulant line for
milliliter per milliliter albumin replacement.
We questioned the ability of our COBE Spectra
Apheresis machine to maintain an adequate interface
with the indicated slow inlet rate, small total blood vol-
ume, and comparatively large extracorporeal circuit.
Would the dwell time be adequate to develop a white cell
layer large enough to allow for depletion? We were as-
sured by COBE, that a successful peripheral stem cell
collection had been performed on a 5.5 kg infant.
Finally, we requested the support of the neonatal in-
tensive care staff and the presence of the attending pe-
diatricians during the procedure, in case we did encoun-
ter difficulties.
THE PROCEDURE
The therapeutic leukapheresis was performed in the
neonatal intensive care unit with the hematology, ne-
phrology, and neonatal physicians, the nurse practitioner,
dialysis and NICU nurses, and two apheresis nurses pres-
ent. The infant remained paralyzed, intubated, and was
receiving ventilatory support.
With heparin infusion started, the dialysis nurse mea-
sured activated clotting times, and gave additional hep-
arin to achieve systemic anticoagulation. The COBE
Spectra was primed with the reconstituted whole blood
and an extra 100 ml was processed to begin cell separa-
tion. An 8 fr Quinton catheter in the right internal jugular
vein provided stable access. We connected our separator
to this line at completion of the blood prime.
A buffy coat was visible within minutes, and we im-
ediately began adjusting the plasma pump rate. We
changed the patient data entry, increasing the patient’s
height and weight, which allowed us to modify the inlet
rate to 10 ml/minute, as recommended by COBE.
Switching into manual mode, we were able to match our
albumin replacement rate through the anticoagulant
pump, with the 2 ml/minute collect pump rate. The tar-
geted inlet volume was increased to accommodate the
blood prime amount. Minor plasma pump adjustments
were needed to maintain a stable interface and achieve a
desirable collection.
Halfway through the depletion, we again increased
our targeted time to collect for approximately 2 hours.
This allowed the dialysis nurse to begin tapering the
heparin dose and decrease the activated clotting time.
When the leukapheresis was complete, we discon-
nected our lines, flushed the baby’s catheter, and dis-
carded the blood filled apheresis tubing.
CONCLUSION
Leukapheresis can be safely performed on even the
smallest children with forethought, planning, and a mul-
tidisciplinary effort.
CONDITION UPDATE
While having battled complications from various
treatments, this 10-month-old infant has undergone suc-
cessful allogeneic bone marrow transplant and presently
is home with her family.
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